After weeks of anticipation, PTC Therapeutics has decided to charge $35,000 a year —depending upon patient weight — for a newly purchased drug for treating Duchenne muscular dystrophy, although the price may be a hard sell to some insurers and families.
The pricing is well below the $89,000 that Marathon Pharmaceuticals planned to charge before selling the decades-old steroid last month to PTC. But whether this lower price is enough to assuage parents or make it worth the $140 million purchase — plus royalties and other payments — is unclear.
About the Author Reprints
